乙型肝炎病毒/丁型肝炎病毒合并感染的肝移植候选者接受乙型肝炎病毒脱氧核糖核酸阳性的同种异体移植物并接受大剂量乙型肝炎免疫球蛋白治疗。
Hepatitis B Virus/Hepatitis D Virus-Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid-Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin.
作者信息
Hammami Muhammad Baraa, Kohli Ruhail, Woreta Tinsay, Sulkowski Mark S, Hamilton James P, Toman Lindsey, Saberi Behnam, Laurin Jacqueline, Wang Jacqueline Garonzik, Philosophe Benjamin, Cameron Andrew M, Gurakar Ahmet
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
出版信息
ACG Case Rep J. 2021 May 12;8(5):e00582. doi: 10.14309/crj.0000000000000582. eCollection 2021 May.
Liver transplantation (LT) for patients with hepatitis D virus (HDV) and hepatitis B virus (HBV) coinfection is uncommon in the United States. Previous case reports described poor outcomes when hepatitis B surface antigen (HBsAg)-positive grafts are transplanted in HBV/HDV-coinfected recipients. However, LT from an HBsAg-negative/HBV-deoxyribonucleic acid-positive donor in an HBV/HDV-coinfected recipient has not been reported. We describe the clinical course and management of an HBV/HDV-coinfected recipient who had LT from an HBsAg-negative/HBV-deoxyribonucleic acid-positive deceased donor and was treated with high-dose hepatitis B immune globulin in combination with an oral tenofovir alafenamide.
在美国，对丁型肝炎病毒（HDV）和乙型肝炎病毒（HBV）合并感染的患者进行肝移植（LT）并不常见。先前的病例报告描述了在HBV/HDV合并感染的受者中移植乙型肝炎表面抗原（HBsAg）阳性移植物时预后较差。然而，尚未有关于在HBV/HDV合并感染的受者中使用HBsAg阴性/HBV脱氧核糖核酸阳性供体进行肝移植的报道。我们描述了一名HBV/HDV合并感染的受者的临床过程及管理情况，该受者接受了来自HBsAg阴性/HBV脱氧核糖核酸阳性脑死亡供体的肝移植，并接受了大剂量乙型肝炎免疫球蛋白联合口服替诺福韦艾拉酚胺治疗。
Zotero 插件